Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate.

Pharmacoecon Open 2019 Jun;3(2):177-188

Analysis Group, Inc., 1000 De La Gauchetière West, Bureau 1200, Montréal, QC, H3B 4W5, Canada.

Objectives: The aim was to compare adherence to antipsychotics (APs), healthcare resource utilization (HRU), and costs before and after once-every-3-months paliperidone palmitate (PP3M) initiation in patients with schizophrenia.

Methods: Medicaid data (Iowa, Kansas, and Missouri; 1/2014-3/2017) were used to identify adults with at least one PP3M claim, ≥ 12 months of pre-index enrollment, and at least two schizophrenia diagnoses. Adequate treatment with once-monthly paliperidone palmitate (PP1M) was required pre-PP3M transition. Generalized estimating equations were used to assess linear trends in adherence to APs, HRU, and costs over the four quarters pre-PP3M transition, and to compare monthly HRU and costs 6 months pre- and 12 months post-PP3M transition as well as adherence to APs 12 months pre- and post-PP3M transition.

Results: Among 324 patients initiated on PP3M, the mean age was 41.4 years and 36.1% were females. Over the four quarters pre-PP3M transition, the monthly number of emergency room visits, medical costs, and inpatient costs decreased, while pharmacy costs and adherence to APs increased. For patients with ≥ 12 months of follow-up (n = 151), adherence to APs (66.2 vs. 70.2%, p = 0.3758), total (US$3371 vs. US$3456; p = 0.7000), pharmacy (US$1805 vs. US$1870; p = 0.2960), and medical costs (US$1565 vs. US$1586; p = 0.9040) remained similar pre- and post-PP3M transition, while mean monthly number of 1-day mental institute visits (1.71 vs. 1.51; p < 0.01) and associated costs (US$260 vs. US$232, p = 0.01) decreased.

Conclusions: Adherence to APs, HRU, and costs were similar pre- and post-PP3M transition, suggesting that PP3M has no impact on monthly costs for patients adequately treated with PP1M, with the added flexibility of once-every-3-months dosing.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s41669-018-0089-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533354PMC
June 2019
9 Reads

Publication Analysis

Top Keywords

adherence aps
16
hru costs
12
paliperidone palmitate
12
pre-pp3m transition
12
once-every-3-months paliperidone
8
healthcare resource
8
post-pp3m transition
8
pre- post-pp3m
8
quarters pre-pp3m
8
costs
8
transition monthly
8
medical costs
8
resource utilization
8
monthly number
8
adherence
6
aps
5
transition
5
transitionresults 324
4
324 patients
4
post-pp3m transitionresults
4

References

(Supplied by CrossRef)

HY Chong et al.
Neuropsychiatr Dis Treat 2016

EQ Wu et al.
J Clin Psychiatry 2005

M Cloutier et al.
J Clin Psychiatry 2016

JA Lieberman et al.
N Engl J Med 2005

D Pilon et al.
BMC Psychiatry. 2017

M Birnbaum et al.
Patient Prefer Adher. 2008

SC Marcus et al.
J Manag Care Spec Pharm. 2015

L Alphs et al.
J Clin Psychiatry 2015

JA Pesa et al.
Curr Med Res Opin 2017

Similar Publications